Korea's No. 30 new drug K-CAB advances to Thailand
Nov.21, 2019
Korea's No. 30 new drug K-CAB advances to Thailand
- CJ HealthCare exports K-CAB Tab. to Pond's Chemical in Thailand
- K-CAB Tab. advances to Thailand following Korea, China, Vietnam, Indonesia and Central and South America
K-CAB Tab., a new drug developed by CJ HealthCare, will enter Thailand following China, Vietnam, Indonesia, and 17 Central and South American countries. K-CAB, meaning ‘made in Korea P-CAB-based new drug, P-CAB of korea' is a new drug for GERD. The drug has received an enthusiastic response, recording 18.7 billion won in 8 months after it was released in Korea.
CJ HealthCare (CEO Kang Seok-Hee) announced on the 21st that they signed an export contract with Pond's Chemical (CEO Mr. Panya, hereinafter Pond’s) of a Thai pharmaceutical company, at the Pond's headquarters located in Bangkok, Thailand on the export of K-CAB Tab. (ingredient name: tegoprazan), a new drug for GERD.
CJ Healthcare will be supplying finished product of K-CAB Tab. to Pond’s for 10 years. K-CAB in Thailand is expected to be released around 2022 after approval.
Pond’s, which has partnered with CJ HealthCare, is a Thai pharmaceutical company that has a range of treatments for GERD such as antacids and PPI-based new drugs. The company has improved new drugs and generic products for various diseases such as sterile water for injection and eye drops. In the case of sterile water for injection and eye drops, it has strength in sales power to foster it as the No. 1 product in the market through active sales and marketing activities.
Pond’s, which introduced the new drug K-CAB Tab., plans to grow K-CAB Tab. as the leading treatment in the GERD market in Thailand, based on its power to increase the number of sterile water for injection and eye drops to the top in the market.
Kang Seok-Hee, CEO of CJ HealthCare, expressed his wishes, “we are delighted to introduce K-CAB Tab., the first P-CAB drug in Korea, to Thailand. In the future, we will foster K-CAB Tab. as Korea No.1 new drug by actively promoting and expanding strategies to enter overseas markets.”
K-CAB Tab. is a new drug for GERD of a new mechanism of action (P-CAB; potassium competitive acid blocker), and it was released in Korea this March. It is expected to exceed 20 billion won in the first year of launch due to the advantages such as fast drug efficacy and convenience that can be taken with or without meals.
Meanwhile, the GERD market in Thailand is about $76 million last year (about KRW 91.2 billion, based on IQVIA DATA) based on the representative PPI.